Market closedADR
Evotec/EVO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Evotec
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Ticker
EVO
Sector
Trading on
Industry
Life Sciences Tools & Services
Headquarters
Employees
5,022
Website
Evotec Metrics
BasicAdvanced
$1.2B
Market cap
-
P/E ratio
-$1.06
EPS
1.13
Beta
-
Dividend rate
Price and volume
Market cap
$1.2B
Beta
1.13
52-week high
$12.00
52-week low
$2.85
Average daily volume
88K
Financial strength
Current ratio
1.834
Quick ratio
1.564
Long term debt to equity
42.333
Total debt to equity
46.814
Interest coverage (TTM)
2.10%
Management effectiveness
Return on assets (TTM)
0.97%
Return on equity (TTM)
-15.62%
Valuation
Price to revenue (TTM)
0.702
Price to book
1.08
Price to tangible book (TTM)
1.52
Price to free cash flow (TTM)
-2.254
Growth
Revenue change (TTM)
-1.25%
Earnings per share change (TTM)
64.97%
3-year revenue growth (CAGR)
13.36%
3-year earnings per share growth (CAGR)
11.63%
What the Analysts think about Evotec
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Evotec stock.
Evotec Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Evotec Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Evotec News
AllArticlesVideos
Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development
Benzinga·2 weeks ago
Evotec and Novo Nordisk forge technology development partnership
Reuters·2 weeks ago
Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell Therapies
Accesswire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Evotec stock?
Evotec (EVO) has a market cap of $1.2B as of October 08, 2024.
What is the P/E ratio for Evotec stock?
The price to earnings (P/E) ratio for Evotec (EVO) stock is 0 as of October 08, 2024.
Does Evotec stock pay dividends?
No, Evotec (EVO) stock does not pay dividends to its shareholders as of October 08, 2024.
When is the next Evotec dividend payment date?
Evotec (EVO) stock does not pay dividends to its shareholders.
What is the beta indicator for Evotec?
Evotec (EVO) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.